Medac Disodium Pamidronate 30mgRely on Time Tested Bisphosphonate
Bone Metastasis is a common complication of malignancy. It causes considerable morbidity with pain, impaired mobility, hypercalcemia, pathologic fractures, spinal cord compression & bone marrow infiltration.
Bisphosphonates are the current standard of care for preventing skeletal complications associated with bone metastasis. How Pamidronate works?
• It prevents recruitment of osteoclast precursors
• Prevents maturation of osteoclasts
• Prevents binding of mature osteoclasts to bone surface
• Induces apoptosis (programmed cell death)
WELL KNOWN ESTABLISHED BENEFITS & EFFECTS OF MEDAC PAMIDRONATE• Established therapy with long term results [14]
• Equivalent efficacy to Zoledronic acid [15]
• No routine pre-dose renal monitoring
• Ready to use solution
• Cost effective therapy from a EUROPEAN source
Brief Prescribing Information:Trade Name: Medac Disodium Pamidronate. Qualitative & Quantitative composition. Each ml sterile concentrate for solution for infusion contains 3 mg Pamidronate disodium as pamidronic acid 2.527 mg. 1 vial with 30 ml concentrate for solution for infusion contains 30 mg Pamidronate disodium. Indications: Predominantly lytic bone metastases and multiple myeloma. Tumor induced hypercalcaemia. Paget’s disease of bone. Dosage: By slow intravenous infusion only. Bone metastases and multiple myeloma: 90 mg single infusion every 4 weeks or every 3 weeks if chemotherapy for bone metastases is at 3 weekly intervals. Tumor –induced hypercalcaemia: Total dose 30-90 mg in single or multiple infusions. Paget’s disease of bone: 30 mg weekly or 60 mg every other week up to a total dose of 180-210 mg. No dose adjustment in mild to moderate renal impairment. The use of Medac disodium Pamidronate is not recommended in severe renal impairment except in case of life threatening tumor-induced hypercalcaemia. Contradiction: Hypersensitivity to Medac disodium Pamidronate or other bisphosphonates. Precautions/Warnings: Do not administer as a bolus injection or with other bisphosphonates or calcium containing intravenous infusions. Caution is advised in cases of renal impairment, cardiac disease. Avoid use during pregnancy or breast feeding. Adverse Reactions: Very common: mild, transient fever, hypocalcaemia and hypophosphataemia, mostly asymptomatic. Common: anaemia, thrombocytopenia, lymphocytopenia, headache, insomnia, somnolence; Conjunctivitis; hypertension; nausea, vomiting, anorexia, abdominal pain, diarrhea, constipation, gastritis; skin rash; transient bone pain, joint pain transient musculoskeletal pain; reactions at infusion site; hypokalaemia, hypomagnesaemia, increase in serum creatinine.
